Derivation and validation of a simple clinical bedside score (ATLAS) for Clostridium difficile infection which predicts response to therapy

BMC Infectious Diseases

Volumn 13, Issue 1, 2013, Pages

  Miller, Mark A ^a   Louie, Thomas ^b   Mullane, Kathleen ^c   Weiss, Karl ^d   Lentnek, Arnold ^e   Golan, Yoav ^f   Kean, Yin ^g   Sears, Pam ^g  

^a MCGILL UNIVERSITY   (Canada)

^b UNIVERSITY OF CALGARY   (Canada)

^c UNIVERSITY OF CHICAGO   (United States)

^d MAISONNEUVE ROSEMONT HOSPITAL   (Canada)

^e Wellstar Infectious Disease   (United States)

^f TUFTS MEDICAL CENTER   (United States)

^g Optimer Pharmaceuticals Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; CREATININE; FIDAXOMICIN; VANCOMYCIN; ANTIINFECTIVE AGENT;

ACCURACY; ADULT; AGE; AGED; ARTICLE; ATLAS SCORE; CLINICAL EFFECTIVENESS; CLOSTRIDIUM DIFFICILE INFECTION; CREATININE BLOOD LEVEL; DISEASE SEVERITY; DRUG EFFICACY; HUMAN; INSTRUMENT VALIDATION; LEUKOCYTE COUNT; OUTCOME ASSESSMENT; PATIENT ASSESSMENT; PATIENT CODING; PREDICTION; SCORING SYSTEM; TREATMENT RESPONSE; CLINICAL MEDICINE; CLOSTRIDIUM INFECTION; DIAGNOSTIC PROCEDURE; EVALUATION; FEMALE; MALE; METHODOLOGY; MIDDLE AGED; PATHOLOGY; PROGNOSIS; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; CLINICAL LABORATORY TECHNIQUES; CLINICAL MEDICINE; CLOSTRIDIUM INFECTIONS; FEMALE; HUMANS; MALE; MIDDLE AGED; PROGNOSIS; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 84875301622     PISSN: None     EISSN: 14712334     Source Type: Journal    
DOI: 10.1186/1471-2334-13-148     Document Type: Article

References (23)

1. Jarvis WR, Schlosser J, Jarvis AA, Chinn RY. National point prevalence of clostridium difficile in US health care facility inpatients, 2008. Am J Infect Control 2009, 37:263-270. 10.1016/j.ajic.2009.01.001, 19278754.
2. Loo VG, Poirier L, Miller MA. A predominantly clonal multi-insitutional outbreak of clostridium difficile-associated diarrhea with high morbidity and mortality. New Engl J Med 2005, 353:2442-2449. 10.1056/NEJMoa051639, 16322602.
3. Goorhuis A, Bakker D, Corver J. Emergence of clostridium difficile infection due to a new hypervirulent strain, polymerase chain reaction ribotype 078. Clin Infect Dis 2008, 47:1162-1170. 10.1086/592257, 18808358.
4. Louie TG, Miller MA, Mullane KM. Fidaxomicin versus vancomycin for clostridium difficile infection. New Engl J Med 2011, 364:422-431. 10.1056/NEJMoa0910812, 21288078.
5. Sougioultzis S, Kyne L, Drudy D, Keates S, Maroo S, Pothoulakis C, Giannasca PJ, Lee CK, Warny M, Monath TP, Kelly CP,. Clostridium difficile toxoid vaccine in recurrent C. difficile-associated diarrhea Clostridium difficile toxoid vaccine in recurrent C. Difficile-associated diarrhea. Gastroenterology 2005, 128:764-770. 10.1053/j.gastro.2004.11.004, 15765411, Clostridium difficile toxoid vaccine in recurrent C. difficile-associated diarrhea.
6. Lowy I, Molrine DC, Leav BA. Treatment with monoclonal antibodies against clostridium difficile toxins. N Engl J Med 2010, 362:197-205. 10.1056/NEJMoa0907635, 20089970.
7. Rubin MS, Bodenstein LE, Kent KC. Severe clostridium difficile colitis. Dis Colon Rectum 1995, 38:350-354. 10.1007/BF02054220, 7720439.
8. Belmares J, Gerding DN, Parada JP, Miskevics S, Weaver F, Johnson S. Outcome of metronidazole therapy for clostridium difficile disease and correlation with a scoring system. J Infect 2007, 55:495-501. 10.1016/j.jinf.2007.09.015, 17983659.
9. McEllistrem MC, Carman RJ, Gerding DN, Genheimer CW, Zheng L. A hospital outbreak of clostridium difficile disease associated with isolates carrying binary toxin genes. Clin Infect Dis 2005, 40:265-272. 10.1086/427113, 15655746.
10. Zar FA, Bakkanagari SR, Moorthi KM, Davis MB. A comparison of vancomycin and metronidazole for the treatment of clostridium difficile-associated diarrhea, stratified by disease severity. Clin Infect Dis 2007, 45:302-307. 10.1086/519265, 17599306.
11. Henrich TJ, Krakower D, Bitton A, Yokoe DS. Clinical risk factors for severe clostridium difficile-associated disease. Emerg Infect Dis 2009, 15:415-422. 10.3201/eid1503.080312, 2681109, 19239754.
12. Louie T, Gerson M, Grimard D. Results of a phase III trial comparing tolevamer, vancomycin and metronidazole in patients with clostridium difficile-associated diarrhea (CDAD). program and abstracts of the 47th annual interscience conference on antimicrobial agents and chemotherapy 2007, Chicago, Illinois: Abstract K-425a, September 17-20.
13. Gujja D, Friedenberg FK. Predictors of serious complications due to clostridium difficile infection. Aliment Pharmacol Ther 2009, 29:635-642. 10.1111/j.1365-2036.2008.03914.x, 19077106.
14. UPHS guidelines for antimicrobial therapy 2011, http://www.uphs.upenn.edu/bugdrug/. Last accessed November 7.
15. Fujitani S, George WL, Murthy AR. Comparison of clinical severity score indices for clostridium difficile infection. Infection Control & Hospital Epidemiology 2011, 32:220-228. 10.1086/658336, 23547143.
16. Toro DH, Amaral-Mojica KM, Rocha-Rodriguez R, Gutierrez-Nunez J. An innovative severity score index for C. Difficile infection: a prospective study. Infect Dis in Clin Practice 2011, 19:336-339.
17. Brouwers MC, Rawski E, Spithoff K, Oliver TK. Inventory of cancer guidelines: a tool to advance the guideline enterprise and improve the uptake of evidence. Expert Review of Pharmacoeconomics & Outcomes Research 2011, 11:151-161. 10.1586/erp.11.11, 23512146.
18. Levy MM, Dellinger RP, Townsend SR. The surviving sepsis campaign: results of an international guideline-based performance improvement program targeting severe sepsis. Intensive Care Med 2010, 36:222-231. 10.1007/s00134-009-1738-3, 2826633, 20069275.
19. Cohen SH, Gerding DN, Johnson S. Clinical practice guidelines for clostridium difficile infection in adults: 2010 update by the society for healthcare epidemiology of America (SHEA) and the infectious diseases society of America (IDSA). Infection Control & Hospital Epidemiology 2010, 31:431-455. 10.1086/651706, 23547143.
20. Bauer MP, Kuijper EJ, van Dissel JT. European society of clinical microbiology and infectious diseases (ESCMID): treatment guidance document for clostridium difficile infection (CDI). Clin Microbiol Infect 2009, 15:1067-1079. 10.1111/j.1469-0691.2009.03099.x, 19929973.
21. Crook DW, Walker AS, Kean Y. Fidaxomicin versus vancomycin for Clostridium difficile infection: meta-analysis of pivotal randomized controlled trials. Clin Infect Dis 2012, 55(Supp 2):S93-S103. 3388031, 22752871.
22. Corter JE, Gluck MA. Explaining basic categories: feature predictability and information. Psychol Bull 1992, 111:291-303.
23. Miller M, Gravel D, Mulvey M. Health care-associated clostridium difficile infection in Canada: patient age and infecting strain type are highly predictive of severe outcome and mortality. Clin Infect Dis 2010, 50:194-201. 10.1086/649213, 20025526.